Who makes Gastroview?

Gastroview is developed by University of Alabama at Birmingham.

What development phase is Gastroview in?

Gastroview is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Gastroview

University of Alabama at Birmingham · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Gastroview
Also known as	diatrizoate meglumine and diatrizoate sodium solution USP
Sponsor	University of Alabama at Birmingham
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol (NA)
Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gastroview CI brief — competitive landscape report
Gastroview updates RSS · CI watch RSS
University of Alabama at Birmingham portfolio CI